2023 World Conference on Lung Cancer (Posters)-EP02.01. TP53 Mutation Has Significant Impact on Other Driver Genes in Lung Cancer

EP02.01. TP53 Mutation Has Significant Impact on Other Driver Genes in Lung Cancer - PDF(Abstract)

Pdf Summary

This presentation at the 2023 World Conference on Lung Cancer focused on the genetic characteristics of TP53, the most commonly mutated driver gene in cancer. The study aimed to determine the co-mutations of TP53 and their correlation with tumor mutational burden (TMB) in lung cancer.<br /><br />A total of 1932 lung cancer tissue samples were collected and analyzed using next-generation sequencing (NGS) to obtain mutation information. The results showed that 46% of patients had TP53 mutations, and 57% had at least one site mutation of EGFR, another important gene in lung cancer.<br /><br />TP53 mutations were found to co-occur with CDKN2 and ARB1 mutations, while being mutually exclusive with CDK4, BRCA2, ATM, and ALK mutations. EGFR mutations were only co-mutated with CTNNB1 and showed no significant interaction with the other genes.<br /><br />The study also investigated the influence of TP53 mutations on other genes. RB1 was found to be the most commonly mutated gene associated with TP53, while EGFR, KRAS, and ALK exclusively mutated with TP53 alterations. The mutation patterns were classified into four distinct categories based on TP53 and EGFR mutations, and different signatures in most mutated genes were observed. APC, PIK3CA, and ERBB2 were the most frequent mutations among these categories.<br /><br />Furthermore, the analysis showed that TP53 mutation had a greater impact on TMB than EGFR mutation.<br /><br />In conclusion, TP53 mutations are mutually exclusive with most driver genes and significantly impact the mutation frequency of other genes and TMB. This suggests that TP53 mutations may independently contribute to tumor genesis and development in lung cancer.

Asset Subtitle

Yaxian Yang

Meta Tag

Speaker Yaxian Yang

Topic Tumor Biology: Preclinical Biology - Molecular Therapeutic Targets

Keywords

TP53

genetic characteristics

driver gene

cancer

co-mutations

tumor mutational burden

lung cancer

next-generation sequencing

EGFR

mutation information